Mujallar kimiyya a ranar Talata ta janye binciken da aka yi na Maris 2020 wanda ya gabatar da duniya ga hydroxychloroquine a farkon cutar ta COVID-19 - kuma ta tabbatar da cewa bai cancanci kulawa ba tun daga farko… The International Journal of Antimicrobial Agents, wanda mallakar Elsevier da International Society of Antimicrobial Chemotherapy, ya ba da sanarwar ja da baya.
USA Today, Disamba 18, 2024
Kafin barkewar cutar ta Covid-19, yawancin mutane ba su yi tunani kaɗan ga mujallolin likita, kamfanonin harhada magunguna, da hukumomin gwamnati ba. Duk wani tunanin wucewa yana iya haɗawa da ra'ayin cewa mujallolin likitanci sun kasance masu sahihanci, ana samar da magunguna masu taimako, mai biyan harajin da aka ba da kuɗin FDA yana gwadawa sosai don aminci da inganci kafin amincewa da samfurori, kuma kafofin watsa labaru suna yin iyakar ƙoƙarinsu don bayar da rahoton bangarorin biyu na kowane labari.
Yanzu mu mafi sani.
Abin kunya na Duniya
Abubuwan da aka ambata a sama USA Today labarin ya bayyana cewa binciken da ja da baya shine "kusuwar abin kunya na duniya." Gaskiya ne, amma ba don dalilan da wakilin ya nuna ba. A hakika, Harin da aka yi wa Raoult wata kwakkwarar shaida ce cewa sojojin da suka cutar da jama'ar duniya yayin barkewar cutar ta Covid-19 suna ci gaba da yin aiki ba tare da katsewa ba, tare da lalata lafiyarmu da lafiyarmu.
A da za mu ɗauka cewa Jarida ya san abin da yake yi, cewa binciken Raoult ya cancanci sokewa, kuma hakan USA Today yana bayar da daidaiton rahoto kan halin da ake ciki. Bayan haka, menene yawancin mutane suka sani game da bincike da nazarin likita? Hatta waɗanda ke fagen aikin likitanci sukan dogara ga abin da suke karantawa a cikin ƙwararrun mujallolin don su taimaka su ci gaba da kasancewa da zamani kan sabbin hanyoyin magani. Jama'a suna tsammanin kafofin watsa labarai su kasance masu bin diddigin cin hanci da rashawa na kamfanoni da na gwamnati, amma an ci amanar mu.
Hukuncin Masu adawa da Labarin Aiki
Halin Didier Raoult alama ce ta ɓacin rai wanda aka bayyana a duk faɗin masana'antar kiwon lafiya, kafofin watsa labarai, da na ka'idoji yayin bala'in. Dangane da ja da baya bayan shekaru hudu na binciken Raoult's hydroxychloroquine (HCQ), yi la'akari da abin da ke gaba daga littafina, Hanyoyin cutarwa: Magunguna a Lokacin Covid-19, Cibiyar Brownstone ta buga a watan Afrilu na wannan shekara:
A Marseilles, Faransa, tawagar Dr. Didier Raoult sun gudanar da wani nazarin marasa lafiya 1,061 An yi maganin Covid tare da haɗin HCQ da azithromycin daga 3 ga Maris zuwa Afrilu 9, 2020. Binciken ya ruwaito, "An sami kyakkyawan sakamako na asibiti da kuma maganin virological a cikin marasa lafiya 973 a cikin kwanaki 10 (91.7%)."*
Binciken ya ci gaba da cewa, "Haɗin HCQ-AZ, lokacin da aka fara shi nan da nan bayan ganewar asali, magani ne mai aminci da inganci ga COVID-19, tare da adadin mace-mace na 0.5%, a cikin tsofaffin marasa lafiya. Yana guje wa lalacewa kuma yana kawar da juriya da kamuwa da cuta a mafi yawan lokuta."
Masanin kimiyyar kwayoyin halitta da na asibiti, a lokacin wannan binciken Raoult shine kwararre kan cututtuka masu yaduwa da aka fi bugawa a Turai, kuma shine wanda ya kafa kuma shugaban asibitin bincike na IHN Mediterranee, babban cibiyar cutar cututtuka a Faransa. Raoult ya saba da binciken farko na HCQ a matsayin mai hana cutar ci gaban cutar coronavirus. Wataƙila rahoton nasa ya yi tasiri a cikin amincewar farko na FDA na HCQ don kula da Covid.
HCQ ta kasance kan-da-counter a Faransa shekaru da yawa kafin wasu abubuwan da suka faru a bayan fage siyasa Maneuvering ya kai ga reclassification a matsayin "abu mai guba" a cikin Janairu 2020.
Lokacin da Raoult ya fitar da bincikensa a watan Mayu 2020, umarnin don HCQ ya tashi daga matsakaita na 50 a kowace rana zuwa ɗari da yawa, sannan har ma dubbai. Gwamnatin Faransa da sauri ya dauki mataki don ba da shawarar kada a rubuta shi ga Covid sai dai a cikin gwaje-gwajen asibiti, a wani bangare dangane da gurbatattun Nazarin Surgisphere.
Raoult ya ci gaba da samun nasara ta amfani da HCQ, hade da wasu magunguna, a matsayin magani ga Covid-19. Daga Maris 2020 zuwa Disamba 2021 Raoult ya gudanar da wata ƙungiya ta baya-bayan nan binciken na marasa lafiya 30,423 Covid-19. Wani samfurin da aka riga aka buga na binciken ya kammala da cewa, "HCQ da aka tsara da wuri ko kuma a makare yana ba da kariya daga wani bangare daga mutuwar COVID-19."
Zai bayyana cewa Raoult ya toka gidan zoho a cikin gudanar da nazarin yau da kullun ta amfani da magungunan yau da kullun tare da bayanan bayanan aminci na shekaru da yawa. Bayan an buga pre-bugu na binciken a cikin Maris 2023, rukuni na Hukumomin bincike na Faransa ya yi kira da a ladabtar da Raoult don "rubutun magunguna daban-daban kamar hydroxychloroquine, zinc, ivermectin da azithromycin ga marasa lafiya da ke fama da Covid-19 ba tare da ingantaccen tushen harhada magunguna ba kuma ba su da wata hujja ta tasirin su."
Kawai don dubawa: Hydroxychloroquine da ivermectin suna cikin jerin mahimman magunguna na Hukumar Lafiya ta Duniya kuma kusan ba su da illa ko mu'amala da wasu magunguna. Zinc shine sinadari mai mahimmanci da ake samu a cikin nau'ikan kayan shuka da abinci na dabba kuma ana samun su ta sigar kwaya a kowane kantin magani. Azithromycin wani maganin rigakafi ne wanda aka yi wa wajabta da yawa shekaru da yawa kuma shine mahimmin magani na WHO. Likitoci da yawa da daruruwan karatu sun sami cikakkiyar shaida cewa waɗannan da sauran magungunan kashe-kashen suna da tasiri wajen kula da marasa lafiyar Covid. Menene waɗannan ƙungiyoyin bincike na Faransa suka damu da haka?
Kafofin watsa labarai na son zuciya suna haifar da cutar da jama'a
Bayani da hanyoyin haɗin yanar gizon da ke sama an cire su daga Hanyoyin cutarwa duk sun fito ne daga majiyoyin da aka samu a bainar jama’a, waɗanda yakamata ‘yan jarida su samu lokacin da suke ɗaukar irin waɗannan labaran. Madadin haka, sau da yawa kafofin watsa labarai na Legacy suna da kyakkyawar alaƙa tare da dalolin talla na Big Pharma, da hukumomin gudanarwa na gwamnati. A cikin yanayin wannan labarin USA Today, ya bayyana ɗan jarida ya ɗauki zance da bayanan da waɗanda ke da sha'awar ɓata sunan Didier Raoult suka ba shi, ba tare da gabatar da wani ɓangaren labarin ba, wanda ke nufin wannan musamman. USA Today labarin ya fi farfaganda fiye da labarai.
Hydroxychloroquine Yana da Lafiya Sai in An Ba da shi cikin Magungunan Magunguna
The USA Today Labarin ya nakalto Societyungiyar Magungunan Magunguna da Magunguna ta Faransa tana cewa takardar Raoult "ta kasance tabbataccen misali na rashin da'a na kimiyya… don gabatar da maganin a cikin ƙarya a matsayin mai tasiri ga Covid-19." Al'umma sun yi iƙirarin, ba tare da kawo wata shaida ba, cewa aikin Raoult ya haifar da "haɗari maras tabbas ga miliyoyin mutane da yiwuwar dubban mutuwar da za a iya gujewa."
An yi amfani da Hydroxychloroquine don fiye da shekaru 60 don magance zazzabin cizon sauro da sauran cututtuka, kuma yana da kyakkyawan yanayin tsaro wanda hakan yake ana ba mata masu ciki da yara akai-akai. Magani ne da ba a iya siyar da shi ba a ƙasashe da yawa. The zargin "mummunan illa" daga HCQ kawai yana faruwa idan mai haƙuri ya wuce gona da iri, hujjar da mashawarcin Hukumar Lafiya ta Duniya, H. Weniger, ya yi hayar a 1979 don duba abubuwan da suka faru na manya. guba ta magungunan chloroquine.
Dokta Richard Urso, Wani mai ba da shawara na farko na amfani da HCQ don magance Covid-19, ya ce, "Duk yanayin siyasar ya haifar da tsoro ga wannan maganin." Ya yi bayanin cewa bayanin martabar amincin HCQ ya fi aspirin, Motrin, da Tylenol, amma ya lura cewa manyan gwaje-gwajen asibiti da aka gwada HCQ akan Covid-19 an saita su don gazawa. Dokta Urso ya ce "sun yi amfani da allurai masu guba masu yawa kuma suna tunanin abin da suka gano? Lokacin da kuka yi amfani da allurai masu guba, kuna samun sakamako mai guba." Ya bayyana cewa HCQ yana maida hankali ne a cikin huhu, wanda shine inda cutar Covid-19 ke tasowa. Dr. Urso ya lura cewa hade da zinc, HCQ yana da matukar tasiri a matsayin duka rigakafi da farkon maganin cutar Covid-19.
Weintz, Lori. Hanyoyin cutarwa: Magunguna a Lokacin Covid-19 (shafi na 69). Cibiyar Brownstone. Kindle Edition.
Dr. Urso, Dr. Raoult, da wasu da yawa, ciki har da Dr. Tony Fauci, sun san a farkon cutar cewa hydroxychloroquine shine babban ɗan takara don maganin Covid-19. Cibiyoyin Lafiya na Ƙasa (NIH) karatu An gano a cikin 2005 cewa chloroquine, mafarin HCQ, shine "mai iya hana kamuwa da cutar SARS da kuma yaduwa" a cikin nazarin al'adun tantanin halitta. Chloroquine ya kuma nuna alƙawari akan MERS a cikin vitro. USA Today ya kasa ambaton wannan tarihin da ya dace game da HCQ.
Elsevier da Mujallar Likitan da aka Rarraba
The USA Today Labarin yana nuna rashin sha'awar Elsevier, wanda ya mallaki mujallar da ta janye binciken Raoult.
Wikipedia ya gano elsevier a matsayin "kamfanin wallafe-wallafen ilimi na Dutch wanda ya ƙware a cikin kimiyya, fasaha, da abun ciki na likitanci." Taken Elsevier's shashen yanar gizo "Don amfanin al'umma," kuma ya ce, "Muna taimaka wa masu bincike da ƙwararrun kiwon lafiya su ci gaba da kimiyya da inganta sakamakon kiwon lafiya."
Duk da haka, Elsevier kamfani ne na biliyoyin daloli don riba wanda ya mallaki yawancin mujallolin likitanci da na kimiyya, kuma majiyoyi da yawa sun zarge shi da yin mummunan tasiri akan raba bincike. Babban farashin biyan kuɗin sa, da goyon bayan ƙungiyoyin da ke son hana buɗaɗɗen shiga labarai da karatu, ya haifar da biyan kuɗi.
Duk da yake ana samun cikakkun bayanan, samun damar yin amfani da cikakken rubutun labarai galibi ana biyansu-kowa-ne-kone ko ta hanyar biyan kuɗi, har ma don nazarin da kuɗin harajin jama'a ke bayarwa. Har ila yau, Elsevier ya haifar da yanayi inda wasu lokuta ana toshe masu bincike daga aikin da aka buga saboda manufofin kamfani akan bincike da haƙƙin mallaka. Kwamitin edita na mujallu (sau da yawa masu zaman kansu) sun yi murabus saboda takaddama da Elsevier game da farashi, kuma ma'aikatan ɗakin karatu sun kaurace wa Elsevier don mayar da martani ga tsarin farashi.
Duk da yake yin watsi da tsarin kasuwancin Elsevier na ƙasa da daraja, da USA Today labarin ya lura kawai 3 daga cikin 18 marubutan binciken da aka janye sun yarda su janye shi. Jagoran marubuci Didier Raoult baya cikin ukun, kuma a fili ba shi, ko duk wanda zai iya raba ra'ayi game da labarin, ba a yi hira da shi ba.
FDA ta amince da HCQ don magance Covid-19
The USA Today "A cikin 2020, Shugaba Donald Trump na lokacin ya ce ya kasance shan hydroxychloroquine don hana kamuwa da cutar COVID-19, duk da gargaɗin da Hukumar Abinci da Magunguna ta Amurka (FDA) ta yi kan ingancinta.” Duk da haka, in Mayu 2020 lokacin da Pres. Trump ya ce yana shan HCQ, yin amfani da gaggawa ne da FDA ta ba da izini don magance Covid-19, kuma ana gwada shi a cikin gwaje-gwajen asibiti da yawa. Sai a ranar 15 ga Yuni, 2020 cewa FDA ta soke amincewar EUA ga HCQ don kula da Covid-19, yana mai cewa "sanannun kuma yuwuwar fa'idodin chloroquine da hydroxychloroquine ba su wuce sananne da haɗarin haɗari don amfani da izini ba."
FDA ta ambaci damuwa game da "abubuwan da suka faru na zuciya da kuma sauran cututtuka masu tsanani," da "sakamako na baya-bayan nan daga babban gwajin asibiti na asibiti a marasa lafiya." Kamar yadda aka fada a baya munanan illa masu illa daga HCQ zai haifar ne kawai daga wuce gona da iri. Ana iya samun cikakkun bayanai da ke bayan ɓarna na gwajin gwajin asibiti na HCQ azaman jiyya ga Covid-19 nan, amma gajeriyar sigar a bayan dalili shi ne: Ina rantsuwa da Dokokin FDA, ƙarƙashin sashe na 564 na Dokar FD&C, FDA na iya ba da izinin Amfani da Gaggawa kawai ga rigakafin gwaji idan babu wani ingantaccen magani.
Idan Covid-19 za a iya bi da ita yadda ya kamata tare da riga-kafin da FDA ta amince da su, irin su hydroxychloroquine da ivermectin, ba za a sami wata hujja ta doka don ba da izinin Amfani da Gaggawa ga allurar rigakafin Covid a cikin haɓakawa.
Weintz, Lori. Hanyoyin cutarwa: Magunguna a Lokacin Covid-19 (shafi na 74). Cibiyar Brownstone. Kindle Edition.
Labari kamar na USA Today shafi da ake magana a kai a cikin wannan post ɗin yana da matsala ba kawai don abin da yake faɗi ba, amma saboda abin da bai faɗi ba. Ainihin labarin shine yadda tuni FDA ta amince da magunguna, waɗanda likitoci da yawa ke samun tasiri wajen kula da Covid-19, an lalata su kuma an danne su don samar da fa'ida sosai, rashin gwadawa, rashin inganci, da cutarwa ga Amfani da Gaggawa Magunguna da alluran rigakafi.
Rikici na Sha'awa a FDA da NIH
Akwai buƙatar raba Big Pharma da sauran daloli na ɓangare na uku daga biyan su ga hukumomin gudanarwa. Akusan rabin Hukumar Abinci da Magunguna (FDA) kasafin kudin ya fito ne daga kamfanonin harhada magunguna waɗanda FDA ta amince da kuma tsara su.
A wani rikici na sha'awa, Cibiyoyin Lafiya na Ƙasa (NIH) masana kimiyya sun karɓa sarauta akan binciken samfur. An kwatanta NIH akan gidan yanar gizon ta a matsayin "Hukumar bincike ta likitancin kasa," tare da biliyoyin daloli na masu biyan haraji da ke zuwa bincike kowace shekara. Rahoton Mayu 2022 daga ƙungiyar sa ido na gwamnati Buɗe Littattafai ya lura cewa, "A zahiri, kuɗin masu biyan haraji na bayar da tallafin bincike na NIH yana amfanar masu binciken da NIH ke aiki saboda an jera su azaman masu ƙirƙira haƙƙin mallaka don haka suna karɓar biyan kuɗin sarauta daga masu lasisi." Bude Littattafan kiyasin "an biya har dala miliyan 350 na sarauta daga wasu masana kimiyya na NIH a cikin shekarun kasafin kudi tsakanin 2010 da 2020."
Bude Littattafai, bayanin kula, "Lokacin da ma'aikacin NIH ya yi bincike a matsayinsa na hukuma, NIH ta mallaki haƙƙin kowane haƙƙin mallaka. Waɗannan haƙƙin mallaka suna da lasisi don amfani da kasuwanci ga kamfanonin da za su iya amfani da su don kawo kayayyaki zuwa kasuwa." Bude Littattafan ya ce, "[N] ɗaya daga cikin waɗannan biyan kuɗi yana karɓar duk wani bincike ko da yaushe kuma har ya kai ga kamfani [yana] biyan kuɗi ga ko dai jagoranci ko masana kimiyya, yayin da kuma ke karɓar tallafi ... to, a kan fuskarsa akwai rikici na sha'awa."
Kodayake hukumomi daban-daban, duka biyun suna ƙarƙashin inuwar Lafiya da Ayyukan Jama'a, a cikin 2010 NIH da FDA sun shiga cikin Yarjejeniya ta Ƙungiyar Jagoranci don sauƙaƙe "haɗin kai tsakanin NIH da FDA" la'akari, "NIH da FDA "sun raba manufa daya na inganta lafiyar jama'a ta hanyar inganta fassarar asali da binciken binciken asibiti zuwa samfurori da hanyoyin kwantar da hankali. Hukumomin suna da haɗin kai a cikin ayyukansu da ayyukansu-NIH tana goyan bayan da gudanar da bincike kan ilimin halittu da ɗabi'a kuma FDA tana tabbatar da aminci da ingancin magani da sauran samfuran. Wannan yana da kyau a kan takarda, amma kamar yadda muka samu a cikin shekaru biyar da suka gabata, waɗannan hukumomin ba sa kare lafiyar jama'a.
Akwai kuma matsalar abin da ake kira kofa mai juyawa tsakanin FDA da kamfanonin harhada magunguna. Misali, tara daga cikin 10 na karshe Kwamitin FDAya ci gaba da yin aiki don masana'antar harhada magunguna ko kuma yin hidima a kan kwamitin gudanarwa na kamfanin magunguna bayan barin FDA. Sannan akwai gaskiyar gudummawar kamfen na Big Pharma da kuma zaɓe ga Majalisa. Cikakken kashi biyu bisa uku na Majalisa ta ba da cak daga masana'antar harhada magunguna gabanin zaben 2020 bisa ga labaran STAT.
Babu labarai da yawa akan waɗannan batutuwa a cikin manyan kafofin watsa labarai, saboda tsarin ya lalace sosai. Manya-manyan kuɗi da ƙarfi masu ƙarfi suna bayan tuƙi don kiyaye tsarin na yanzu. Ku lura sau nawa shirinku ko labaranku ke “Pfizer ya kawo muku,” ko wani kamfanin magunguna. Yi la'akari da gaskiyar cewa ƙasashe biyu ne kawai a duniya ke ba da izinin sayar da magunguna kai tsaye zuwa ga jama'a - Amurka da New Zealand. Big Pharma da kamfanoni masu alaƙa da harhada magunguna sun fi ƙarfin tasiri a kan kafofin watsa labaru, mujallolin kimiyya da na likitanci, da hukumomin gwamnatin mu.
Lokaci don girgiza matsayin Quo
Muna buƙatar lissafi, da kuma raba kuɗin Big Pharma daga hukumomin da ke tsara binciken likita da samfuran magunguna. Har ila yau, lokaci ya yi da za a dakatar da tallace-tallace iri-iri waɗanda suka ƙare tare da "tambayi likitan ku game da (cika a sarari)." Idan kafofin watsa labarai na Legacy ba za su iya rayuwa ba tare da dalar tallan Big Pharma ba, to lokaci ya yi da za a yi sabon samfurin watsa labarai.
Tare da gwamnatin Trump mai shigowa, da nadin Robert F. Kennedy Jr. a matsayin darekta na Ma'aikatar Lafiya da Ayyukan Jama'a, muna da damar yin gyaran kwas da ake bukata.
An sake bugawa daga marubucin Mayarwa
Shiga cikin tattaunawar:
An buga ƙarƙashin a Commonirƙirar Commonabi'a Mai Creativeayatarwa 4.0 Licenseasashen Duniya
Don sake bugawa, da fatan za a saita hanyar haɗin yanar gizo zuwa asali Cibiyar Brownstone Labari da Marubuci.
